Medtronic plc (MDT) Q3 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

and we look forward to bringing this unique catheter to the U.S. Beyond Cas, we're also making material progress with Simplicity Spiral for hypertension and AltaViva for urge urinary incontinence. Simplicity delivers a one-time, durable, minimally invasive treatment for hypertension and represents one of our largest growth drivers. Now, this is going to be a contributor for years to come, given the 18 million U.S. patients with uncontrolled hypertension. We're seeing strong patient outcomes in the field, and the RDN value proposition, it resonates with both physicians and patients. Now we've got strong and growing clinical data, a broad label, and expanding reimbursement all in hand. Look, we've built the foundation. Now we're focused on growing this new segment and transforming the hypertension treatment paradigm. We've recently activated our direct-to-consumer Go Beyond campaign in key markets around the U.S., which is resulting in a 50 times increase in website visits versus the prior quarter. So a lot of interest coming in from patients. Building a new market, it does take time. That is something Medtronic knows how to do exceptionally well. And in parallel to building out this new market, we're innovating for the long term. first with our trans-radial catheter, which is on track to launch in the second half of fiscal year 27, and with our spiral Gemini trial evaluating multi-organ ablation to further boost efficacy. Now, similarly, we are scaling AltaViva, our tibial neurostimulation device. AltaViva is a simple yet transformational option for treating urinary incontinence. which is a condition that affects 16 million people in the US. AltaViva is a very small device that requires no imaging, no sedation, activates the same day, is MRI ready, and offers up to 15...